Immunotherapy in melanoma patients with autoimmune disease / 国际肿瘤学杂志

ABSTRACT

Immunotherapy has become an important treatment for melanoma.The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody or programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor is safe and effective for melanoma patients with autoimmune disease (AD).However, when such patients are treated with anti-CTLA-4 antibody or PD-1/PD-L1 inhibitors, their condition changes should be closely monitored to prevent and avoid possible AD progression and immune-related adverse events.